Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 1% during mid-day trading on Friday . The company traded as low as $7.21 and last traded at $7.28. 1,143,010 shares traded hands during trading, a decline of 82% from the average session volume of 6,209,305 shares. The stock had previously closed at $7.35.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Recursion Pharmaceuticals Trading Down 1.4 %

The company has a market capitalization of $1.72 billion, a PE ratio of -4.55 and a beta of 0.83. The stock has a fifty day simple moving average of $8.81 and a 200-day simple moving average of $9.88.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The business had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the previous year, the firm earned ($0.34) earnings per share. The business’s revenue was up 14.0% compared to the same quarter last year. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total transaction of $43,260.00. Following the sale, the chief operating officer now owns 535,457 shares in the company, valued at $3,860,644.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $7.21, for a total value of $43,260.00. Following the transaction, the chief operating officer now owns 535,457 shares in the company, valued at approximately $3,860,644.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 207,359 shares of company stock worth $1,704,435. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its holdings in Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after purchasing an additional 13,777,689 shares in the last quarter. Mubadala Investment Co PJSC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $128,041,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after purchasing an additional 5,680,656 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in Recursion Pharmaceuticals by 161.2% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after purchasing an additional 5,680,656 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Recursion Pharmaceuticals by 37.7% in the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock valued at $118,627,000 after purchasing an additional 4,247,002 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.